|
1
|
Chen L, Magliano DJ and Zimmet PZ: The
world wide epidemiology of type 2 diabetes mellitus-present and
future perspectives. Nat Rew Endocrinol. 8:228–236. 2011.
View Article : Google Scholar
|
|
2
|
Shaw JE, Sicree RA and Zimmet PZ: Global
estimates of the prevalence of diabetes for 2010 and 2030. Diabetes
Res Clin Pract. 87:4–14. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fonseca VA: Defining and characterizing
the progression of type 2 diabetes. Diabetes Care. 32 Suppl
2:S151–S156. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stumvoll M, Goldstein BJ and van Haeften
TW: Type 2 diabetes: Principles of pathogenesis and therapy.
Lancet. 365:1333–1346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Russell ND and Cooper ME: 50 years
forward: Mechanisms of hyperglycemia driven diabetic complications.
Diabetologia. 58:1708–1714. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang ZV and Hill JA: Diabetic
cardiomyopathy: Catabolism driving metabolism. Circulation.
131:771–773. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shi Y and Vanhoutte PM: Macro- and
microvascular endothelial dysfunction in diabetes. J Diaberes.
9:434–449. 2017. View Article : Google Scholar
|
|
8
|
Shih KC, Lam KS and Tong L: A systematic
review on the impact of diabetes mellitus on the ocular surface.
Nutr Diabetes. 7:e2512017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lim AKh: Diabetic
nephropathy-complications and treatment. Int J Nephrol Renovasc
Dis. 7:361–381. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Volmer-Thole M and Lobmann R: Neuropathy
and diabetic foot syndrome. Int J Mol Sci. 17:pii: E917. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lilly MA, Davis MF, Fabie JE, Terhune EB
and Gallicano GI: Current stem cell based therapies in diabetes. Am
J Stem Cells. 5:87–98. 2016.PubMed/NCBI
|
|
12
|
Liu X, Wang Y, Li Y and Pei X: Research
status and prospect of stem cells in the treatment of diabetes
mellitus. Sci China Life Sci. 56:306–312. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Orbay H, Tobita M and Mizuno H:
Mesenchymal stem cells isolated from adipose and other tissues:
Basic biological properties and clinical applications. Stem Cells
Int. 2012:4617182012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cao M, Pan Q, Dong H, Yuan X, Li Y, Sun Z,
Dong X and Wang H: Adipose-derived mesenchymal stem cells improve
glucose homeostasis in hight-fat diet-induced obese mice. Stem Cell
Res The. 6:2082015. View Article : Google Scholar
|
|
15
|
Hao H, Liu J, Shen J, Zhao Y, Liu H, Hou
Q, Tong C, Ti D, Dong L, Cheng Y, et al: Multiple intravenous
infusion of bone marrow mesenchymal stem cells reverse
hyperglycemia in experimental type 2 diabetes rats. Biochem Biophys
Res Commun. 436:418–423. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Aali E, Mirzamohammadi S, Ghaznavi H,
Madjd Z, Larijani B, Rayegan S and Sharifi AM: A comparative study
of mesenchymal stem cell transplantation with its paracrine effect
on control of hyperglycemia in type 1 diabetic rats. J Diabetes
Metab Disord. 13:762014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xie M, Hao HJ, Cheng Y, Xie ZY, Yin YQ,
Zhang Q, Gao JQ, Liu HY, Mu YM and Han WD: Adipose-derived
mesenchymal cells ameliorate hyperglycemia through regulating
hepatic glucose metabolism in type 2 diabetic rats. Biochem Biophys
Res Commun. 483:435–441. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheng SK, Park EY, Pehar A, Rooney AC and
Gallicano GI: Current progress of human trials using stem cell
therapy as a treatment for diabetes mellitus. Am J Stem Cells.
5:74–86. 2016.PubMed/NCBI
|
|
19
|
Si Y, Zhao Y, Hao H, Liu J, Guo Y, Mu Y,
Shen J, Cheng Y, Fu X and Han W: Infusion of mesenchymal stem cells
ameliorates hyperglycemia in type 2 diabetes rats: Identification
of a novel role in improving insulin sensitivity. Diabetes.
61:1616–1625. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pde Bueno G, Yochite JN, Derigge-Pisani
GF, de Farias Malmegrim KC, de Avó LR, Voltarelli JC and Leal ÂM:
Metabolic and pancreatic effects of bone marrow mesenchymal stem
cells transplantation in mice fed high-fat diet. PLoS One.
10:e01243692015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hughey CC, Ma L, James FD, Bracy DP, Wang
Z, Wasserman DH, Rottman JN, Hittel DS and Shearer J: Mesenchymal
stem cell transplantation for the infracted heart: Therapeutic
potential for insulin resistance beyond the heart. Cardiovasc
Diabetol. 12:1282013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shree N and Bhonde RR: Conditioned media
from adipose tissue derived mesenchymal stem cells reverse insulin
resistance in cellular models. J Cell Biochem. 118:2037–2043. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shulman GI, Rothman DL, Jue T, Stein P,
DeFronzo RA and Shulman RG: Quantitation of muscle glycogen
synthesis in normal subjects and subjects with
non-insulin-dependent diabetes by 13C nuclear magnetic resonance
spectroscopy. N Engl J Med. 322:223–228. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Song R, Peng W, Zhang Y, Lv F, Wu HK, Guo
J, Cao Y, Pi Y, Zhang X, Jin L, et al: Central role of E3 ubiquitin
ligase MG53 in insulin resistance and metabolic disorders. Nature.
494:375–379. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yi JS, Park JS, Ham YM, Nguyen N, Lee NR,
Hong J, Kim BW, Lee H, Lee CS, Jeong BC, et al: MG53-induced IRS-1
ubiquitination negatively regulates skeletal myogenesis and insulin
signaling. Nat Commun. 4:23542013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ma H, Liu J, Bian Z, Cui Y, Zhou X, Zhou
X, Zhang B, Adesanya TM, Yi F, Park KH, et al: Effects of metabolic
syndrome on mitsugumin 53 expression and function. PLoS One.
10:e01241282015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee H, Park JJ, Nguyen N, Park JS, Hong J,
Kim SH, Song WY, Kim HJ, Choi K, Cho S, et al: MG53-IRS-1
(Mitsugumin 53-insulin receptor substrate-1) interaction disruptor
sensitizes insulin signaling in skeletal muscle. J Biol Chem.
291:26627–26635. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cai C, Masumiya H, Weisleder N, Matsuda N,
Nishi M, Hwang M, Ko JK, Lin P, Thornton A, Zhao X, et al: MG53
nucleates assembly of cell membrane repair machinery. Nat Cell
Biol. 11:56–64. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tan T, Ko YG and Ma J: Dual function of
MG53 in membrane repair and insulin signaling. BMB Rep. 49:414–423.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang C, Deng ZH, Chen S, Chen S, Zhang JY,
Jin LY, Si YL and Chen GH: Adipose-derived mesenchymal stem cells
alleviating heart dysfunction through suppressing MG53 protein in
rat model of diabetic cardiomyopathy. Int J Clin Exp Pathol.
10:4009–4022. 2017.
|
|
31
|
Rea S and James DE: Moving GLUT4: The
biogenesis and trafficking of GLUT4 storage vesicles. Diabetes.
46:1667–1677. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sylow L, Kleinert M, Pehmøller C, Prats C,
Chiu TT, Klip A, Richter EA and Jensen TE: Akt and Rac1 signaling
are jointly required for insulin-stimulated glucose uptake in
skeletal muscle and downregulated in insulin resistance. Cell
Signal. 26:323–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xie Z, Hao H, Tong C, Cheng Y, Liu J, Pang
Y, Si Y, Guo Y, Zang L, Mu Y and Han W: Human umbilical
cord-derived mesenchymal stem cells elicit macrophages into an
anti-inflammatory phenotype to alleviate insulin resistance in type
2 diabetic rats. Stem Cells. 34:627–639. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Laustsen PG, Michael MD, Crute BE, Cohen
SE, Ueki K, Kulkarni RN, Keller SR, Lienhard GE and Kahn CR:
Lipoatrophic diabetes in Irs1(−/−)/Irs3(−/−) double knockout mice.
Genes Dev. 16:3213–3222. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bunner AE, Chandrasekera PC and Barnard
ND: Knockout mouse models of insulin signaling: Relevance past and
future. Word J Diabetes. 5:146–159. 2014. View Article : Google Scholar
|
